REGN241122P807500
- 16.70
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3
FDA Accepts SNY and REGN's Dupixent Re-Submitted SBLA for Urticaria
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Express News | Regeneron Pharmaceuticals : Deutsche Bank Cuts Target Price to $805 From $900
Check Out What Whales Are Doing With REGN
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron, Sanofi Say Resubmitted Application to Expand Dupixent Label Accepted in U.S.
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment
Express News | Sanofi - Resubmission Includes New Pivotal Data Which Confirm Dupixent Significantly Reduced Itch and Hive Activity
Express News | Dupixent® (Dupilumab) Sbla Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (Csu)
Wolfe Research Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,150
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Regeneron Pharma Initiated at Neutral by Citigroup
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895
Express News | Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at Ash
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock